Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024
02 nov. 2023 07h30 HE
|
Cellectar Biosciences
Reports Preliminary Financial Results for Third Quarter 2023 and Provides a Corporate Update Conference Call scheduled for today at 8:30 am Eastern Time FLORHAM PARK, N.J., Nov. 02, 2023 ...
Cellectar Biosciences Partners with Florida Cancer Specialists & Research Institute to Support the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
25 oct. 2023 08h00 HE
|
Cellectar Biosciences
Strategic collaboration to advance patient care and further define the U.S. treatment landscape First of several planned community-based cancer care network collaborations for Cellectar to...
Cellectar Biosciences to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 2, 2023
24 oct. 2023 08h00 HE
|
Cellectar Biosciences
FLORHAM PARK, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia
17 oct. 2023 08h00 HE
|
Cellectar Biosciences
William Yoon Appointed Vice President, Medical Affairs Aaditya Nanduri Appointed Vice President, Business Strategy and Analytics FLORHAM PARK, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cellectar...
Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants
02 oct. 2023 06h35 HE
|
Cellectar Biosciences
FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia
18 sept. 2023 08h40 HE
|
Cellectar Biosciences
FLORHAM PARK, N.J., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing
11 sept. 2023 06h30 HE
|
Cellectar Biosciences
FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing
05 sept. 2023 08h21 HE
|
Cellectar Biosciences
Transaction led by existing investor Rosalind with participation from other new and existing healthcare-focused institutional investors Pivotal topline data in Waldenstrom’s macroglobulinemia...
Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update
14 août 2023 08h40 HE
|
Cellectar Biosciences
FLORHAM PARK, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization...
Cellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual Meeting
28 juin 2023 08h30 HE
|
Cellectar Biosciences
Interim data from 64 refractory multiple myeloma patients demonstrated an ORR of 28%, a CBR of 70%, and a DCR of 92% Demonstrated a 46% ORR in triple class refractory, 50% ORR in quad-class...